Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.

被引：0
|
作者：
Bitzer, Michael
Horger, Marius
Ganten, Tom M.
Lauer, Ulrich M.
Woerns, Marcus A.
Siveke, Jens T.
Dollinger, Matthias M.
Gerken, Guido
Wege, Henning
Giannini, Edoardo G.
Zagonel, Vittorina
Cillo, Umberto
Trevisani, Franco
Santoro, Armando
Montesarchio, Vincenzo
Hauns, Bernhard
Asche, Julia
Jankowsky, Ruediger
Mais, Anna
Hentsch, Bernd
机构：
[1] Univ Tubingen, Med Univ Clin, Tubingen, Germany
[2] Univ Tubingen, Tubingen, Germany
[3] Heidelberg Univ, Dept Internal Med, Heidelberg, Germany
[4] Med Univ Clin, Mainz, Germany
[5] Tech Univ Munich, Dept Internal Med 2, D-80290 Munich, Germany
[6] Univ Halle Wittenberg, Dept Internal Med, D-06108 Halle, Germany
[7] Univ Duisburg Essen, Dept Gastroenterol & Hepatol, Essen, Germany
[8] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[9] Univ Genoa, Dept Internal Med, Gastroenterol Unit, I-16126 Genoa, Italy
[10] Ist Oncol Veneto IRCCS, Padua, Italy
[11] Azienda Univ Padova, Hepatobiliary Surg & Liver Transplant Unit, Padua, Italy
[12] Univ Bologna, Bologna, Italy
[13] Humanitas Canc Ctr, Dept Oncol, Rozzano, Italy
[14] UO Oncol Osped Cotugno Napoli, Naples, Italy
[15] 4SC AG, Planegg Martinsried, Germany
[16] 4SC AG, Martinsried, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4115
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of vitamin K with sorafenib combination treatment against hepatocellular carcinoma: Open-label, randomized phase II study.
    Haruna, Yoshimichi
    Inoue, Atsuo
    Kawamoto, Seiichi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study
    Haruna, Yoshimichi
    Yakushijin, Takayuki
    Kawamoto, Seiichi
    CANCER MEDICINE, 2021, 10 (03): : 914 - 922
  • [33] A phase I/II study to assess the safety, tolerability and pharmacolkinetics (PK) of intravenous (IV) infusion of MB07133 in subjects with unresectable hepatocellular carcinoma (HCC).
    Ma, B.
    Forbes, W.
    Venook, A. P.
    Bissell, D. M.
    Peterson, C.
    Niculae, I.
    Bullough, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 92S - 92S
  • [34] A phase I/II study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC)
    Duffy, Austin G.
    Ma, Chi
    Ulahannan, Susanna Varkey
    Makarova-Rusher, Oxana V.
    Fioravanti, Suzanne
    Walker, Melissa
    Venkatesan, Aradhana
    Turkbey, Ismail B.
    Choyke, Peter L.
    Trepel, Jane B.
    Cao, Liang
    Compton, Kathryn
    Figg, William Douglas
    Greten, Tim F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [35] The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.
    Yang, Xin-Rong
    Cheng, Jian-Wen
    Wu, Suiyi
    Hu, Bo
    Qiu, Shuang-Jian
    Sun, Hui-Chuan
    Fan, Jia
    Zhou, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Tanwandee, Tawesak
    Sukeepaisarnjaroen, Wattana
    Chan, Stephen Lam
    Choo, SuPin
    Han, Guohong
    Sriuranpong, Virote
    Pan, Hongming
    Yau, Thomas Cheung
    Ren, Zhenggang
    Xu, Jian-Ming
    Peng, Bin
    Saji, Takami
    Sun, Yongjian
    Huang, Alan
    Manenti, Luigi
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).
    Keenan, Bridget
    Griffith, Madeline J.
    Bauer, Kelly
    Bracci, Paige M.
    Behr, Spencer
    Umetsu, Sarah E.
    Gordan, John Dozier
    Ngo, Zoe
    Iqbal, Syma
    Hanna, Diana L.
    Venook, Alan P.
    El-Khoueiry, Anthony B.
    Fong, Lawrence
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [38] Phase II trial investigating the efficacy and safety of sunitinib in patients with unresectable hepatocellular carcinoma (HCC)
    Faivre, S. J.
    Raymond, E.
    Douillard, J.
    Boucher, E.
    Lim, H. Y.
    Kim, J. S.
    Lanzalone, S.
    Lechuga, M. J.
    Sherman, L.
    Cheng, A. L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 270 - 270
  • [39] Phase II study of sorafenib plus tegafur/uracil (UFT) in patients with advanced hepatocellular carcinoma (HCC)
    Shen, Y.
    Shao, Y.
    Hsu, C.
    Hsu, C.
    Lin, Z.
    Chen, P.
    Ding, Y.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met plus hepatocellular carcinoma (HCC) previously treated with sorafenib
    Decaens, T.
    Barone, C.
    Assenat, E.
    Wermke, M.
    Fasolo, A.
    Merle, P.
    Blanc, J-F.
    Grando, V.
    Bruns, R.
    Straub, J.
    Zhao, C.
    Faivre, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 48 - 48
12345